{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:10:25Z","timestamp":1789665025811,"version":"4.0.1"},"reference-count":202,"publisher":"Aging and Disease","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2021]]},"DOI":"10.14336\/ad.2021.0302","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T13:41:37Z","timestamp":1625319697000},"page":"1097","source":"Crossref","is-referenced-by-count":45,"title":["Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management"],"prefix":"10.14336","volume":"12","author":[{"given":"Batool F","family":"Kirmani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Au","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Ayari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"John","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmashri","family":"Shetty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Delorenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2021.0302-1","doi-asserted-by":"crossref","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al (2015). A definition and classification of status epilepticus-Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, 56:1515-23.","DOI":"10.1111\/epi.13121"},{"key":"key-10.14336\/AD.2021.0302-2","doi-asserted-by":"crossref","unstructured":"Lv RJ, Wang Q, Cui T, Zhu F, Shao XQ (2017). Status epilepticus-related etiology, incidence and mortality: A meta-analysis. Epilepsy Res, 136:12-17.","DOI":"10.1016\/j.eplepsyres.2017.07.006"},{"key":"key-10.14336\/AD.2021.0302-3","doi-asserted-by":"crossref","unstructured":"Tiamkao S, Pranbul S, Sawanyawisuth K, Thepsuthammarat K (2014). Integrated Epilepsy Research Group. A national database of incidence and treatment outcomes of status epilepticus in Thailand. Int J Neurosci, 124:416-20.","DOI":"10.3109\/00207454.2013.850084"},{"key":"key-10.14336\/AD.2021.0302-4","doi-asserted-by":"crossref","unstructured":"Shorvon S, Ferlisi M (2011). The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain, 134:2802-18.","DOI":"10.1093\/brain\/awr215"},{"key":"key-10.14336\/AD.2021.0302-5","doi-asserted-by":"crossref","unstructured":"Rai S, Drislane FW (2018). Treatment of Refractory and Super-refractory Status Epilepticus. Neurotherapeutics, 15:697-712.","DOI":"10.1007\/s13311-018-0640-5"},{"key":"key-10.14336\/AD.2021.0302-6","doi-asserted-by":"crossref","unstructured":"Olkkola KT, Ahonen J (2008). Midazolam and other benzodiazepines. Handb Exp Pharmacol, 182:335-60.","DOI":"10.1007\/978-3-540-74806-9_16"},{"key":"key-10.14336\/AD.2021.0302-7","doi-asserted-by":"crossref","unstructured":"Riss J, Cloyd J, Gates J, Collins S (2008). Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand, 118:69-86.","DOI":"10.1111\/j.1600-0404.2008.01004.x"},{"key":"key-10.14336\/AD.2021.0302-8","doi-asserted-by":"crossref","unstructured":"Salonen M, Kanto J, Iisalo E, Himberg JJ (1987). Midazolam as an induction agent in children: a pharmacokinetic and clinical study. Anesth Analg, 66:625-8.","DOI":"10.1213\/00000539-198707000-00007"},{"key":"key-10.14336\/AD.2021.0302-9","unstructured":"Levy Ren\u00e9 H, Anderson GD, Miller JW (2002). Benzodiazepines: chemistry, biotransformation, and pharmacokinetics. In: Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 187-205."},{"key":"key-10.14336\/AD.2021.0302-10","doi-asserted-by":"crossref","unstructured":"Singhi S, Murthy A, Singhi P, Jayashree M (2002). Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol, 17:106-10.","DOI":"10.1177\/088307380201700203"},{"key":"key-10.14336\/AD.2021.0302-11","doi-asserted-by":"crossref","unstructured":"Claassen J, Hirsch LJ, Emerson RG, Mayer SA (2002). Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia, 43:146-53.","DOI":"10.1046\/j.1528-1157.2002.28501.x"},{"key":"key-10.14336\/AD.2021.0302-12","doi-asserted-by":"crossref","unstructured":"Hamano SI, Sugai K, Miki M, Tabata T, Fukuyama T, Osawa M (2019). Efficacy, safety, and pharmacokinetics of intravenous midazolam in Japanese children with status epilepticus. J Neurol Sci, 396:150-158.","DOI":"10.1016\/j.jns.2018.09.035"},{"key":"key-10.14336\/AD.2021.0302-13","doi-asserted-by":"crossref","unstructured":"Fernandez A, Lantigua H, Lesch C, Shao B, Foreman B, Schmidt JM, et al (2014). High-dose midazolam infusion for refractory status epilepticus. Neurology, 82:359-65.","DOI":"10.1212\/WNL.0000000000000054"},{"key":"key-10.14336\/AD.2021.0302-14","doi-asserted-by":"crossref","unstructured":"Walker SE, Iazzetta J (1981). Compatibility and stability of pentobarbital infusions. Anesthesiology, 55:487-9.","DOI":"10.1097\/00000542-198110000-00045"},{"key":"key-10.14336\/AD.2021.0302-15","doi-asserted-by":"crossref","unstructured":"Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA (1987). Pentobarbital pharmacokinetics in patients with severe head injury. Drug Intell Clin Pharm, 21:459-63.","DOI":"10.1177\/106002808702100517"},{"key":"key-10.14336\/AD.2021.0302-16","doi-asserted-by":"crossref","unstructured":"Singh V (2014). Survival after fatal pentobarbital ingestion. Indian J Anaesth, 58:85-6.","DOI":"10.4103\/0019-5049.126838"},{"key":"key-10.14336\/AD.2021.0302-17","doi-asserted-by":"crossref","unstructured":"Kirshbaum RJ, Carollo VJ (1970). Reversible iso-electric EEG in barbiturate coma. JAMA, 212:1215.","DOI":"10.1001\/jama.1970.03170200079022"},{"key":"key-10.14336\/AD.2021.0302-18","doi-asserted-by":"crossref","unstructured":"Drislane FW, KMBBSP W, Hocker S (2018). Treatment of refractory and super-refractory status epilepticus. In: Status Epilepticus A Clinical Perspective. Cham: Springer International Publishing, 201-14.","DOI":"10.1007\/978-3-319-58200-9_17"},{"key":"key-10.14336\/AD.2021.0302-19","doi-asserted-by":"crossref","unstructured":"Pugin D, Foreman B, De Marchis GM, Fernandez A, Schmidt JM, Czeisler BM, Mayer SA, et al (2014). Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care, 18:R103.","DOI":"10.1186\/cc13883"},{"key":"key-10.14336\/AD.2021.0302-20","doi-asserted-by":"crossref","unstructured":"Rossetti AO, Milligan TA, Vulli\u00e9moz S, Michaelides C, Bertschi M, Lee JW (2011). A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care, 14:4-10.","DOI":"10.1007\/s12028-010-9445-z"},{"key":"key-10.14336\/AD.2021.0302-21","doi-asserted-by":"crossref","unstructured":"Cereda C, Berger MM, Rossetti AO (2009). Bowel ischemia: a rare complication of thiopental treatment for status epilepticus. Neurocrit Care, 10:355-8.","DOI":"10.1007\/s12028-008-9168-6"},{"key":"key-10.14336\/AD.2021.0302-22","doi-asserted-by":"crossref","unstructured":"Sabharwal V, Ramsay E, Martinez R, Shumate R, Khan F, Dave H, et al (2015). Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav, 52:264-6.","DOI":"10.1016\/j.yebeh.2015.07.040"},{"key":"key-10.14336\/AD.2021.0302-23","unstructured":"Folino TB, Muco E, Safadi AO, Parks LJ (2020). Propofol. In: StatPearls. Treasure Island: StatPearls Publishing."},{"key":"key-10.14336\/AD.2021.0302-24","doi-asserted-by":"crossref","unstructured":"Ferlisi M, Shorvon S (2012). The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain, 135:2314-28.","DOI":"10.1093\/brain\/aws091"},{"key":"key-10.14336\/AD.2021.0302-25","doi-asserted-by":"crossref","unstructured":"Shorvon S (2011). Super-refractory status epilepticus: an approach to therapy in this difficult clinical situation. Epilepsia, 8:53-6.","DOI":"10.1111\/j.1528-1167.2011.03238.x"},{"key":"key-10.14336\/AD.2021.0302-26","doi-asserted-by":"crossref","unstructured":"Holtkamp M (2018). Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults. Drugs, 78:307-326.","DOI":"10.1007\/s40265-017-0859-1"},{"key":"key-10.14336\/AD.2021.0302-27","doi-asserted-by":"crossref","unstructured":"Hocker S, Tatum WO, LaRoche S, Freeman WD (2014). Refractory and super-refractory status epilepticus-an update. Curr Neurol Neurosci Rep, 14:452.","DOI":"10.1007\/s11910-014-0452-x"},{"key":"key-10.14336\/AD.2021.0302-28","doi-asserted-by":"crossref","unstructured":"Iyer VN, Hoel R, Rabinstein AA (2009). Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med, 37:3024-30.","DOI":"10.1097\/CCM.0b013e3181b08ac7"},{"key":"key-10.14336\/AD.2021.0302-29","doi-asserted-by":"crossref","unstructured":"Hwang WS, Gwak HM, Seo DW (2013). Propofol infusion syndrome in refractory status epilepticus. J Epilepsy Res, 3:21-7.","DOI":"10.14581\/jer.13004"},{"key":"key-10.14336\/AD.2021.0302-30","doi-asserted-by":"crossref","unstructured":"Zhang Q, Yu Y, Lu Y, Yue H (2019). Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus. BMC Neurol, 19:55.","DOI":"10.1186\/s12883-019-1281-y"},{"key":"key-10.14336\/AD.2021.0302-31","doi-asserted-by":"crossref","unstructured":"Sheth RD, Gidal BE (1998). Refractory status epilepticus: response to ketamine. Neurology, 51:1765-6.","DOI":"10.1212\/WNL.51.6.1765"},{"key":"key-10.14336\/AD.2021.0302-32","doi-asserted-by":"crossref","unstructured":"White PF, Way WL, Trevor AJ (1982). Ketamine--its pharmacology and therapeutic uses. Anesthesiology, 56:119-36.","DOI":"10.1097\/00000542-198202000-00007"},{"key":"key-10.14336\/AD.2021.0302-33","doi-asserted-by":"crossref","unstructured":"Fujikawa DG (1995). Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia, 36:186-95.","DOI":"10.1111\/j.1528-1157.1995.tb00979.x"},{"key":"key-10.14336\/AD.2021.0302-34","doi-asserted-by":"crossref","unstructured":"Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al (2013). Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia, 54:1498-503.","DOI":"10.1111\/epi.12247"},{"key":"key-10.14336\/AD.2021.0302-35","doi-asserted-by":"crossref","unstructured":"Rossetti AO, Lowenstein DH (2011). Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol, 10:922-30.","DOI":"10.1016\/S1474-4422(11)70187-9"},{"key":"key-10.14336\/AD.2021.0302-36","doi-asserted-by":"crossref","unstructured":"Quibell R, Prommer EE, Mihalyo M, Twycross R, Wilcock A (2011). Ketamine. J Pain Symptom Manage, 41:640-9.","DOI":"10.1016\/j.jpainsymman.2011.01.001"},{"key":"key-10.14336\/AD.2021.0302-37","doi-asserted-by":"crossref","unstructured":"Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991). NMDA antagonist neurotoxicity: mechanism and prevention. Science, 254:1515-8.","DOI":"10.1126\/science.1835799"},{"key":"key-10.14336\/AD.2021.0302-38","doi-asserted-by":"crossref","unstructured":"Dong C, Anand KJ (2013). Developmental neurotoxicity of ketamine in pediatric clinical use. Toxicol Lett, 220:53-60.","DOI":"10.1016\/j.toxlet.2013.03.030"},{"key":"key-10.14336\/AD.2021.0302-39","doi-asserted-by":"crossref","unstructured":"Dericioglu N, Arslan D, Arsava EM, Topcuoglu MA (2020). Efficacy and Safety of Ketamine in Refractory\/Super-refractory Nonconvulsive Status Epilepticus: Single-Center Experience. Clin EEG Neurosci. 1550059420942677.","DOI":"10.1177\/1550059420942677"},{"key":"key-10.14336\/AD.2021.0302-40","doi-asserted-by":"crossref","unstructured":"H\u00f6fler J, Rohracher A, Kalss G, Zimmermann G, Dobesberger J, Pilz G, et al (2016). (S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study. CNS Drugs, 30:869-76.","DOI":"10.1007\/s40263-016-0371-2"},{"key":"key-10.14336\/AD.2021.0302-41","doi-asserted-by":"crossref","unstructured":"Ying SW, Werner DF, Homanics GE, Harrison NL, Goldstein PA (2009). Isoflurane modulates excitability in the mouse thalamus via GABA-dependent and GABA-independent mechanisms. Neuropharmacology, 56:438-47.","DOI":"10.1016\/j.neuropharm.2008.09.015"},{"key":"key-10.14336\/AD.2021.0302-42","unstructured":"Koblin DD (1992). Characteristics and implications of desflurane metabolism and toxicity. Anesth Analg, 75:S10-6."},{"key":"key-10.14336\/AD.2021.0302-43","doi-asserted-by":"crossref","unstructured":"Mirsattari SM, Sharpe MD, Young GB (2004). Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol, 61:1254-9.","DOI":"10.1001\/archneur.61.8.1254"},{"key":"key-10.14336\/AD.2021.0302-44","doi-asserted-by":"crossref","unstructured":"Zhumadilov A, Gilman CP, Viderman D (2015). Management of super-refractory status epilepticus with isoflurane and hypothermia. Front Neurol, 5:286.","DOI":"10.3389\/fneur.2014.00286"},{"key":"key-10.14336\/AD.2021.0302-45","unstructured":"Khan J, Liu MDesflurane (2020). In: StatPearls. Treasure Island: StatPearls Publishing."},{"key":"key-10.14336\/AD.2021.0302-46","doi-asserted-by":"crossref","unstructured":"Bayrlee A, Ganeshalingam N, Kurczewski L, Brophy GM (2015). Treatment of Super-Refractory Status Epilepticus. Curr Neurol Neurosci Rep, 15:66.","DOI":"10.1007\/s11910-015-0589-2"},{"key":"key-10.14336\/AD.2021.0302-47","doi-asserted-by":"crossref","unstructured":"Perks A, Cheema S, Mohanraj R (2012). Anaesthesia and epilepsy. Br J Anaesth, 108:562-71.","DOI":"10.1093\/bja\/aes027"},{"key":"key-10.14336\/AD.2021.0302-48","doi-asserted-by":"crossref","unstructured":"Morrison KE, Cole AB, Thompson SM, Bale TL (2019). Brexanolone for the treatment of patients with postpartum depression. Drugs Today (Barc), 55:537-544.","DOI":"10.1358\/dot.2019.55.9.3040864"},{"key":"key-10.14336\/AD.2021.0302-49","doi-asserted-by":"crossref","unstructured":"Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, et al (2017). Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol, 82:342-352.","DOI":"10.1002\/ana.25008"},{"key":"key-10.14336\/AD.2021.0302-50","doi-asserted-by":"crossref","unstructured":"Paul SM, Purdy RH (1992). Neuroactive steroids. FASEB J, 6:2311-22.","DOI":"10.1096\/fasebj.6.6.1347506"},{"key":"key-10.14336\/AD.2021.0302-51","unstructured":"Morrow AL, Pace JR, Purdy RH, Paul SM (1990). Characterization of steroid interactions with gamma-aminobutyric acid receptor-gated chloride ion channels: evidence for multiple steroid recognition sites. Mol Pharmacol, 37:263-70."},{"key":"key-10.14336\/AD.2021.0302-52","doi-asserted-by":"crossref","unstructured":"Farrant M, Nusser Z (2005). Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci, 6:215-29.","DOI":"10.1038\/nrn1625"},{"key":"key-10.14336\/AD.2021.0302-53","doi-asserted-by":"crossref","unstructured":"Chuang SH, Reddy DS (2020). Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam. J Pharmacol Exp Ther, 372:285-298.","DOI":"10.1124\/jpet.119.261735"},{"key":"key-10.14336\/AD.2021.0302-54","unstructured":"Chamberlain JM, Kapur J, Shinnar S, Elm J, Holsti M, Babcock L, et al (2020). Neurological Emergencies Treatment Trials; Pediatric Emergency Care Applied Research Network investigators. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet, 395:1217-1224."},{"key":"key-10.14336\/AD.2021.0302-55","doi-asserted-by":"crossref","unstructured":"Craig S (2005). Phenytoin poisoning. Neurocrit Care, 3:161-70.","DOI":"10.1385\/NCC:3:2:161"},{"key":"key-10.14336\/AD.2021.0302-56","doi-asserted-by":"crossref","unstructured":"Yaari Y, Selzer ME, Pincus JH (1986). Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol, 20:171-84.","DOI":"10.1002\/ana.410200202"},{"key":"key-10.14336\/AD.2021.0302-57","doi-asserted-by":"crossref","unstructured":"Hanson JW, Smith DW (1976). Fetal hydantoin syndrome. Lancet, 1:692.","DOI":"10.1016\/S0140-6736(76)92805-1"},{"key":"key-10.14336\/AD.2021.0302-58","doi-asserted-by":"crossref","unstructured":"Krasowski MD, Penrod LE (2012). Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Med Inform Decis Mak, 12:7.","DOI":"10.1186\/1472-6947-12-7"},{"key":"key-10.14336\/AD.2021.0302-59","doi-asserted-by":"crossref","unstructured":"Hamed SA (2017). The auditory and vestibular toxicities induced by antiepileptic drugs. Expert Opin Drug Saf, 16:1281-1294.","DOI":"10.1080\/14740338.2017.1372420"},{"key":"key-10.14336\/AD.2021.0302-60","doi-asserted-by":"crossref","unstructured":"Guldiken B, R\u00e9mi J, Noachtar S (2016). Cardiovascular adverse effects of phenytoin. J Neurol, 263:861-870.","DOI":"10.1007\/s00415-015-7967-1"},{"key":"key-10.14336\/AD.2021.0302-61","doi-asserted-by":"crossref","unstructured":"Polat I, Karaoglu P, Ayanoglu M, Yis U, Hiz S (2015). Life-Threatening and Rare Adverse Effects of Phenytoin. Pediatr Emerg Care, 31:e3.","DOI":"10.1097\/PEC.0000000000000495"},{"key":"key-10.14336\/AD.2021.0302-62","doi-asserted-by":"crossref","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al (2016). Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in Children and Adults: Report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr, 16:48-61.","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"key-10.14336\/AD.2021.0302-63","doi-asserted-by":"crossref","unstructured":"Shaner DM, McCurdy SA, Herring MO, Gabor AJ (1988). Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology, 38:202-7.","DOI":"10.1212\/WNL.38.2.202"},{"key":"key-10.14336\/AD.2021.0302-64","doi-asserted-by":"crossref","unstructured":"Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al (1998). A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med, 339:792-8.","DOI":"10.1056\/NEJM199809173391202"},{"key":"key-10.14336\/AD.2021.0302-65","doi-asserted-by":"crossref","unstructured":"Noureen N, Khan S, Khursheed A, Iqbal I, Maryam M, Sharib SM, Maheshwary N (2019). Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: An Open-Label Randomized Controlled Trial. J Clin Neurol, 15:468-472.","DOI":"10.3988\/jcn.2019.15.4.468"},{"key":"key-10.14336\/AD.2021.0302-66","doi-asserted-by":"crossref","unstructured":"Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N (2007). Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure, 16:527-32.","DOI":"10.1016\/j.seizure.2007.04.012"},{"key":"key-10.14336\/AD.2021.0302-67","doi-asserted-by":"crossref","unstructured":"Fischer JH, Patel TV, Fischer PA (2003). Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. Clin Pharmacokinet, 42:33-58.","DOI":"10.2165\/00003088-200342010-00002"},{"key":"key-10.14336\/AD.2021.0302-68","doi-asserted-by":"crossref","unstructured":"Ramsay RE, DeToledo J (1996). Intravenous administration of fosphenytoin: options for the management of seizures. Neurology, 46:S17-9.","DOI":"10.1212\/WNL.46.6_Suppl_1.17S"},{"key":"key-10.14336\/AD.2021.0302-69","doi-asserted-by":"crossref","unstructured":"Browne TR (1997). Fosphenytoin (Cerebyx). Clin Neuropharmacol, 20:1-12.","DOI":"10.1097\/00002826-199702000-00001"},{"key":"key-10.14336\/AD.2021.0302-70","doi-asserted-by":"crossref","unstructured":"Pop\u0142awska M, Borowicz KK, Czuczwar SJ (2015). The safety and efficacy of fosphenytoin for the treatment of status epilepticus. Expert Rev Neurother, 15:983-92.","DOI":"10.1586\/14737175.2015.1074523"},{"key":"key-10.14336\/AD.2021.0302-71","doi-asserted-by":"crossref","unstructured":"Gerber N, Mays DC, Donn KH, Laddu A, Guthrie RM, Turlapaty P, et al (1988). Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin. J Clin Pharmacol, 28:1023-32.","DOI":"10.1002\/j.1552-4604.1988.tb03124.x"},{"key":"key-10.14336\/AD.2021.0302-72","doi-asserted-by":"crossref","unstructured":"DeToledo JC, Ramsay RE (2000). Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf, 22:459-66.","DOI":"10.2165\/00002018-200022060-00004"},{"key":"key-10.14336\/AD.2021.0302-73","doi-asserted-by":"crossref","unstructured":"Chang CW, Bleck TP (1995). Status epilepticus. Neurol Clin, 13:529-48.","DOI":"10.1016\/S0733-8619(18)30033-1"},{"key":"key-10.14336\/AD.2021.0302-74","unstructured":"Boucher BA, Feler CA, Dean JC, Michie DD, Tipton BK, Smith KR Jr, et al (1996). The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy, 16:638-45."},{"key":"key-10.14336\/AD.2021.0302-75","doi-asserted-by":"crossref","unstructured":"Patel SI, Birnbaum AK, Cloyd JC, Leppik IE (2015). Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy. CNS Drugs, 29:1009-22.","DOI":"10.1007\/s40263-015-0289-0"},{"key":"key-10.14336\/AD.2021.0302-76","doi-asserted-by":"crossref","unstructured":"Srivastava K, Bhartiya S, Gavli V, Patil R, Rajadhyaksha S (2020). Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus. Indian Pediatr, 57:218-221.","DOI":"10.1007\/s13312-020-1754-5"},{"key":"key-10.14336\/AD.2021.0302-77","unstructured":"Suddock JT, Cain MD (2020). Barbiturate Toxicity. In: StatPearls. Treasure Island: StatPearls Publishing."},{"key":"key-10.14336\/AD.2021.0302-78","doi-asserted-by":"crossref","unstructured":"Wilensky AJ, Friel PN, Levy RH, Comfort CP, Kaluzny SP (1982). Kinetics of phenobarbital in normal subjects and epileptic patients. Eur J Clin Pharmacol, 23:87-92.","DOI":"10.1007\/BF01061382"},{"key":"key-10.14336\/AD.2021.0302-79","doi-asserted-by":"crossref","unstructured":"Trinka E, H\u00f6fler J, Leitinger M, Brigo F (2015). Pharmacotherapy for Status Epilepticus. Drugs, 75:1499-521.","DOI":"10.1007\/s40265-015-0454-2"},{"key":"key-10.14336\/AD.2021.0302-80","doi-asserted-by":"crossref","unstructured":"Yasiry Z, Shorvon SD (2014). The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure, 23:167-74.","DOI":"10.1016\/j.seizure.2013.12.007"},{"key":"key-10.14336\/AD.2021.0302-81","doi-asserted-by":"crossref","unstructured":"Byun JI, Chu K, Sunwoo JS, Moon J, Kim TJ, Lim JA, et al (2015). Mega-dose phenobarbital therapy for super-refractory status epilepticus. Epileptic Disord, 17:444-52.","DOI":"10.1684\/epd.2015.0778"},{"key":"key-10.14336\/AD.2021.0302-82","doi-asserted-by":"crossref","unstructured":"Mirski MA, Williams MA, Hanley DF (1995). Prolonged pentobarbital and phenobarbital coma for refractory generalized status epilepticus. Crit Care Med, 23:400-4.","DOI":"10.1097\/00003246-199502000-00028"},{"key":"key-10.14336\/AD.2021.0302-83","doi-asserted-by":"crossref","unstructured":"Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E (2007). Safety of rapid intravenous loading of valproate. Epilepsia, 48:478-83.","DOI":"10.1111\/j.1528-1167.2007.00989.x"},{"key":"key-10.14336\/AD.2021.0302-84","doi-asserted-by":"crossref","unstructured":"Trinka E, H\u00f6fler J, Zerbs A, Brigo F (2014). Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs, 28:623-39.","DOI":"10.1007\/s40263-014-0167-1"},{"key":"key-10.14336\/AD.2021.0302-85","doi-asserted-by":"crossref","unstructured":"Perucca E (2002). Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs, 16:695-714.","DOI":"10.2165\/00023210-200216100-00004"},{"key":"key-10.14336\/AD.2021.0302-86","doi-asserted-by":"crossref","unstructured":"Misra UK, Kalita J, Patel R (2006). Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology, 67:340-2.","DOI":"10.1212\/01.wnl.0000224880.35053.26"},{"key":"key-10.14336\/AD.2021.0302-87","doi-asserted-by":"crossref","unstructured":"Mehta V, Singhi P, Singhi S (2007). Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol, 22:1191-7.","DOI":"10.1177\/0883073807306248"},{"key":"key-10.14336\/AD.2021.0302-88","doi-asserted-by":"crossref","unstructured":"Malamiri RA, Ghaempanah M, Khosroshahi N, Nikkhah A, Bavarian B, Ashrafi MR (2012). Efficacy and safety of intravenous sodium valproate versus phenobarbital in controlling convulsive status epilepticus and acute prolonged convulsive seizures in children: a randomised trial. Eur J Paediatr Neurol, 16:536-41.","DOI":"10.1016\/j.ejpn.2012.01.012"},{"key":"key-10.14336\/AD.2021.0302-89","doi-asserted-by":"crossref","unstructured":"Chen L, Feng P, Wang J, Liu L, Zhou D (2009). Intravenous sodium valproate in mainland China for the treatment of diazepam refractory convulsive status epilepticus. J Clin Neurosci, 16:524-6.","DOI":"10.1016\/j.jocn.2008.06.007"},{"key":"key-10.14336\/AD.2021.0302-90","doi-asserted-by":"crossref","unstructured":"Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, Lampl Y (2008). Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand, 118:296-300.","DOI":"10.1111\/j.1600-0404.2008.01097.x"},{"key":"key-10.14336\/AD.2021.0302-91","doi-asserted-by":"crossref","unstructured":"Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, et al (2013). Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol, 4:192.","DOI":"10.3389\/fneur.2013.00192"},{"key":"key-10.14336\/AD.2021.0302-92","doi-asserted-by":"crossref","unstructured":"Gidal BE, Balt\u00e8s E, Otoul C, Perucca E (2005). Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res, 64:1-11.","DOI":"10.1016\/j.eplepsyres.2005.01.005"},{"key":"key-10.14336\/AD.2021.0302-93","doi-asserted-by":"crossref","unstructured":"Otoul C, Arrigo C, van Rijckevorsel K, French JA (2005). Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol, 28:72-8.","DOI":"10.1097\/01.wnf.0000159956.87511.67"},{"key":"key-10.14336\/AD.2021.0302-94","doi-asserted-by":"crossref","unstructured":"Kirmani B (2014). Role of intravenous levetiracetam in acute seizure management. Front Neurol, 5:109.","DOI":"10.3389\/fneur.2014.00109"},{"key":"key-10.14336\/AD.2021.0302-95","doi-asserted-by":"crossref","unstructured":"Yi ZM, Zhong XL, Wang ML, Zhang Y, Zhai SD (2020). Efficacy, Safety, and Economics of Intravenous Levetiracetam for Status Epilepticus: A Systematic Review and Meta-Analysis. Front Pharmacol, 11:751.","DOI":"10.3389\/fphar.2020.00751"},{"key":"key-10.14336\/AD.2021.0302-96","doi-asserted-by":"crossref","unstructured":"Aceves J, Khan O, Mungall D, Fonkem E, Wright C, Wenner A, Kirmani B (2013). Efficacy and tolerability of intravenous levetiracetam in childrens. Front Neurol, 4:120.","DOI":"10.3389\/fneur.2013.00120"},{"key":"key-10.14336\/AD.2021.0302-97","doi-asserted-by":"crossref","unstructured":"Kirmani BF, Crisp ED, Kayani S, Rajab H (2009). Role of intravenous levetiracetam in acute seizure management of children. Pediatr Neurol, 41:37-9.","DOI":"10.1016\/j.pediatrneurol.2009.02.016"},{"key":"key-10.14336\/AD.2021.0302-98","doi-asserted-by":"crossref","unstructured":"Khan O, Chang E, Cipriani C, Wright C, Crisp E, Kirmani B (2011). Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol, 44(4):265-9.","DOI":"10.1016\/j.pediatrneurol.2010.11.005"},{"key":"key-10.14336\/AD.2021.0302-99","doi-asserted-by":"crossref","unstructured":"Khan O, Cipriani C, Wright C, Crisp E, Kirmani B (2013). Role of intravenous levetiracetam for acute seizure management in preterm neonates. Pediatr Neurol, 49:340-3.","DOI":"10.1016\/j.pediatrneurol.2013.05.008"},{"key":"key-10.14336\/AD.2021.0302-100","unstructured":"Karao\u011flu P, H\u0131z S, \u0130\u015fcan B, Polat AI, Ayano\u011flu M, Duman N, Yi\u015f U (2020). Intravenous Levetiracetam for Treatment of Seizures in Term and Preterm Neonates. J Pediatr Neurosci, 15:15-20."},{"key":"key-10.14336\/AD.2021.0302-101","doi-asserted-by":"crossref","unstructured":"Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al (2012). Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care, 17:3-23.","DOI":"10.1007\/s12028-012-9695-z"},{"key":"key-10.14336\/AD.2021.0302-102","doi-asserted-by":"crossref","unstructured":"Trinka E, Dobesberger J (2009). New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord, 2:79-91.","DOI":"10.1177\/1756285608100460"},{"key":"key-10.14336\/AD.2021.0302-103","doi-asserted-by":"crossref","unstructured":"Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al (2011). Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand, 123:137-41.","DOI":"10.1111\/j.1600-0404.2010.01423.x"},{"key":"key-10.14336\/AD.2021.0302-104","doi-asserted-by":"crossref","unstructured":"Mir\u00f3 J, Toledo M, Santamarina E, Ricciardi AC, Villanueva V, Pato A, et al (2013). Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure, 22:77-9.","DOI":"10.1016\/j.seizure.2012.10.004"},{"key":"key-10.14336\/AD.2021.0302-105","doi-asserted-by":"crossref","unstructured":"H\u00f6fler J, Trinka E (2013). Lacosamide as a new treatment option in status epilepticus. Epilepsia, 54:393-404.","DOI":"10.1111\/epi.12058"},{"key":"key-10.14336\/AD.2021.0302-106","doi-asserted-by":"crossref","unstructured":"Strzelczyk A, Z\u00f6llner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al (2017). Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia, 58:933-950.","DOI":"10.1111\/epi.13716"},{"key":"key-10.14336\/AD.2021.0302-107","doi-asserted-by":"crossref","unstructured":"Kellinghaus C, Berning S, Besselmann M (2009). Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav, 14:429-31.","DOI":"10.1016\/j.yebeh.2008.12.009"},{"key":"key-10.14336\/AD.2021.0302-108","doi-asserted-by":"crossref","unstructured":"Koubeissi MZ, Mayor CL, Estephan B, Rashid S, Azar NJ (2011). Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand, 123:142-6.","DOI":"10.1111\/j.1600-0404.2010.01430.x"},{"key":"key-10.14336\/AD.2021.0302-109","doi-asserted-by":"crossref","unstructured":"Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd (2011). The use of lacosamide in refractory status epilepticus. Neurocrit Care, 14:348-53.","DOI":"10.1007\/s12028-010-9501-8"},{"key":"key-10.14336\/AD.2021.0302-110","doi-asserted-by":"crossref","unstructured":"Santamarina E, Toledo M, Sueiras M, Raspall M, Ailouti N, Lainez E, et al (2013). Usefulness of intravenous lacosamide in status epilepticus. J Neurol, 260:3122-8.","DOI":"10.1007\/s00415-013-7133-6"},{"key":"key-10.14336\/AD.2021.0302-111","doi-asserted-by":"crossref","unstructured":"Abend NS, Dlugos DJ (2008). Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol, 38:377-90.","DOI":"10.1016\/j.pediatrneurol.2008.01.001"},{"key":"key-10.14336\/AD.2021.0302-112","doi-asserted-by":"crossref","unstructured":"Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ (2003). The use of topiramate in refractory status epilepticus. Neurology, 60:332-4.","DOI":"10.1212\/01.WNL.0000042783.86439.27"},{"key":"key-10.14336\/AD.2021.0302-113","doi-asserted-by":"crossref","unstructured":"Bensalem MK, Fakhoury TA (2003). Topiramate and status epilepticus: report of three cases. Epilepsy Behav, 4:757-60.","DOI":"10.1016\/j.yebeh.2003.07.016"},{"key":"key-10.14336\/AD.2021.0302-114","doi-asserted-by":"crossref","unstructured":"Kahriman M, Minecan D, Kutluay E, Selwa L, Beydoun A (2003). Efficacy of topiramate in children with refractory status epilepticus. Epilepsia, 44:1353-6.","DOI":"10.1046\/j.1528-1157.2003.11803.x"},{"key":"key-10.14336\/AD.2021.0302-115","doi-asserted-by":"crossref","unstructured":"Santamarina E, Parejo Carbonell B, Sala J, Guti\u00e9rrez-Viedma \u00c1, Mir\u00f3 J, et al (2019). Use of intravenous brivaracetam in status epilepticus: A multicenter registry. Epilepsia, 60:1593-1601.","DOI":"10.1111\/epi.16094"},{"key":"key-10.14336\/AD.2021.0302-116","doi-asserted-by":"crossref","unstructured":"Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, et al (2016). Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia, 57:201-9.","DOI":"10.1111\/epi.13267"},{"key":"key-10.14336\/AD.2021.0302-117","doi-asserted-by":"crossref","unstructured":"Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, et al (2017). Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav, 70:177-181.","DOI":"10.1016\/j.yebeh.2017.03.028"},{"key":"key-10.14336\/AD.2021.0302-118","doi-asserted-by":"crossref","unstructured":"Ho CJ, Lin CH, Lu YT, Shih FY, Hsu CW, Tsai WC, Tsai MH (2019). Perampanel Treatment for Refractory Status Epilepticus in a Neurological Intensive Care Unit. Neurocrit Care, 31:24-29.","DOI":"10.1007\/s12028-019-00704-9"},{"key":"key-10.14336\/AD.2021.0302-119","doi-asserted-by":"crossref","unstructured":"Beretta S, Padovano G, Stabile A, Coppo A, Bogliun G, Avalli L, Ferrarese C (2018). Efficacy and safety of perampanel oral loading in postanoxic super-refractory status epilepticus: A pilot study. Epilepsia, 59:243-248.","DOI":"10.1111\/epi.14492"},{"key":"key-10.14336\/AD.2021.0302-120","doi-asserted-by":"crossref","unstructured":"Rohracher A, H\u00f6fler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I, et al (2015). Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav, 49:354-8.","DOI":"10.1016\/j.yebeh.2015.04.005"},{"key":"key-10.14336\/AD.2021.0302-121","doi-asserted-by":"crossref","unstructured":"Strzelczyk A, Knake S, K\u00e4lvi\u00e4inen R, Santamarina E, Toledo M, Willig S, et al (2019). Perampanel for treatment of status epilepticus in Austria, Finland, Germany, and Spain. Acta Neurol Scand, 139:369-376.","DOI":"10.1111\/ane.13061"},{"key":"key-10.14336\/AD.2021.0302-122","doi-asserted-by":"crossref","unstructured":"Newey CR, Mullaguri N, Hantus S, Punia V, George P (2019). Super-Refractory Status Epilepticus Treated with High Dose Perampanel: Case Series and Review of the Literature. Case Rep Crit Care, 2019:3218231.","DOI":"10.1155\/2019\/3218231"},{"key":"key-10.14336\/AD.2021.0302-123","doi-asserted-by":"crossref","unstructured":"Huddart R, Leeder JS, Altman RB, Klein TE (2018). PharmGKB summary: clobazam pathway, pharmacokinetics. Pharmacogenet Genomics, 28:110-115.","DOI":"10.1097\/FPC.0000000000000327"},{"key":"key-10.14336\/AD.2021.0302-124","doi-asserted-by":"crossref","unstructured":"Ng YT, Collins SD (2007). Clobazam. Neurotherapeutics, 4:138-44.","DOI":"10.1016\/j.nurt.2006.11.002"},{"key":"key-10.14336\/AD.2021.0302-125","doi-asserted-by":"crossref","unstructured":"Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA (2011). OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology, 77:1473-81.","DOI":"10.1212\/WNL.0b013e318232de76"},{"key":"key-10.14336\/AD.2021.0302-126","doi-asserted-by":"crossref","unstructured":"Sivakumar S, Ibrahim M, Parker D Jr, Norris G, Shah A, Mohamed W (2015). Clobazam: An effective add-on therapy in refractory status epilepticus. Epilepsia, 56:e83-9.","DOI":"10.1111\/epi.13013"},{"key":"key-10.14336\/AD.2021.0302-127","doi-asserted-by":"crossref","unstructured":"Farrokh S, Bon J, Erdman M, Tesoro E (2019). Use of Newer Anticonvulsants for the Treatment of Status Epilepticus. Pharmacotherapy, 39:297-316.","DOI":"10.1002\/phar.2229"},{"key":"key-10.14336\/AD.2021.0302-128","unstructured":"Rufinamide for seizures. Aust Prescr. (2019). 42:38-39."},{"key":"key-10.14336\/AD.2021.0302-129","doi-asserted-by":"crossref","unstructured":"Thompson AGB, Cock HR (2016). Successful treatment of super-refractory tonic status epilepticus with rufinamide: First clinical report. Seizure, 39:1-4.","DOI":"10.1016\/j.seizure.2016.04.003"},{"key":"key-10.14336\/AD.2021.0302-130","doi-asserted-by":"crossref","unstructured":"Rossetti AO (2012). Hypothermia in refractory status epilepticus. Crit Care, 16:A26.","DOI":"10.1186\/cc11284"},{"key":"key-10.14336\/AD.2021.0302-131","doi-asserted-by":"crossref","unstructured":"Orlowski JP, Erenberg G, Lueders H, Cruse RP (1984). Hypothermia and barbiturate coma for refractory status epilepticus. Crit Care Med, 12:367-72.","DOI":"10.1097\/00003246-198404000-00006"},{"key":"key-10.14336\/AD.2021.0302-132","doi-asserted-by":"crossref","unstructured":"Zhou J, Poloyac SM (2011). The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol, 7:803-16.","DOI":"10.1517\/17425255.2011.574127"},{"key":"key-10.14336\/AD.2021.0302-133","doi-asserted-by":"crossref","unstructured":"Rana A, Musto AE (2018). The role of inflammation in the development of epilepsy. J Neuroinflammation, 15:144.","DOI":"10.1186\/s12974-018-1192-7"},{"key":"key-10.14336\/AD.2021.0302-134","doi-asserted-by":"crossref","unstructured":"Arya R, Rotenberg A (2019). Dietary, immunological, surgical, and other emerging treatments for pediatric refractory status epilepticus. Seizure, 68:89-96.","DOI":"10.1016\/j.seizure.2018.09.002"},{"key":"key-10.14336\/AD.2021.0302-135","doi-asserted-by":"crossref","unstructured":"Gaspard N, Hirsch LJ, Sculier C, Loddenkemper T, van Baalen A, Lancrenon J, et al (2018). New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. Epilepsia, 59:745-752.","DOI":"10.1111\/epi.14022"},{"key":"key-10.14336\/AD.2021.0302-136","doi-asserted-by":"crossref","unstructured":"Lopinto-Khoury C, Sperling MR (2013). Autoimmune status epilepticus. Curr Treat Options Neurol, 15:545-56.","DOI":"10.1007\/s11940-013-0252-7"},{"key":"key-10.14336\/AD.2021.0302-137","doi-asserted-by":"crossref","unstructured":"Zaccara G, Giannasi G, Oggioni R, Rosati E, Tramacere L, Palumbo P (2017). convulsive status epilepticus study group of the uslcentro Toscana, Italy. Challenges in the treatment of convulsive status epilepticus. Seizure, 47:17-24.","DOI":"10.1016\/j.seizure.2017.02.015"},{"key":"key-10.14336\/AD.2021.0302-138","doi-asserted-by":"crossref","unstructured":"Kadoya M, Onoue H, Kadoya A, Ikewaki K, Kaida K (2015). Refractory status epilepticus caused by anti-NMDA receptor encephalitis that markedly improved following combination therapy with rituximab and cyclophosphamide. Intern Med, 54:209-13.","DOI":"10.2169\/internalmedicine.54.2047"},{"key":"key-10.14336\/AD.2021.0302-139","unstructured":"Kaneko J, Iizuka T, Asari H, et al (2013). Retrospective Review of 6 Patients with New-Onset Refractory Status Epilepticus (NORSE) Syndrome: Early Intervention with Intravenous Cyclophosphamide May Improve Outcome. Neurology, 80:P07.171."},{"key":"key-10.14336\/AD.2021.0302-140","doi-asserted-by":"crossref","unstructured":"Trinka E, Brigo F (2019). Neurostimulation in the treatment of refractory and super-refractory status epilepticus. Epilepsy Behav, 101:106551.","DOI":"10.1016\/j.yebeh.2019.106551"},{"key":"key-10.14336\/AD.2021.0302-141","doi-asserted-by":"crossref","unstructured":"Schneegans H, Stetefeld H, Dohmen C, Onur OA, Lehnhardt FG (2019). Successful Treatment of Super-Refractory Status Epilepticus with High-Intensity Electroconvulsive Therapy - A Case Report and Review of the Current Literature. J Epilepsy Res, 9:76-82.","DOI":"10.14581\/jer.19008"},{"key":"key-10.14336\/AD.2021.0302-142","doi-asserted-by":"crossref","unstructured":"P\u0159ikryl R, Ustohal L, Kucerov\u00e1 HP, Ceskov\u00e1 E (2011). Effect of electroconvulsive therapy on cortical excitability in a patient with long-term remission of schizophrenia: a transcranial magnetic stimulation study. J ECT, 27:e9-11.","DOI":"10.1097\/YCT.0b013e3181dbf785"},{"key":"key-10.14336\/AD.2021.0302-143","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-L\u00f3pez B, G\u00f3mez-Men\u00e9ndez AI, V\u00e1zquez-S\u00e1nchez F, P\u00e9rez-Cabo E, Isidro-Mesas F, Zabalegui-P\u00e9rez A, et al (2020). Electroconvulsive Therapy in Super Refractory Status Epilepticus: Case Series with a Defined Protocol. Int J Environ Res Public Health, 17:11.","DOI":"10.3390\/ijerph17114023"},{"key":"key-10.14336\/AD.2021.0302-144","doi-asserted-by":"crossref","unstructured":"Incecik F, Horoz OO, Herguner OM, Y\u0131ld\u0131zdas D, Altunbasak S (2015). Electroconvulsive therapy for refractory status epilepticus in a child: A case report. Ann Indian Acad Neurol, 18:364-5.","DOI":"10.4103\/0972-2327.157250"},{"key":"key-10.14336\/AD.2021.0302-145","doi-asserted-by":"crossref","unstructured":"Pinchotti DM, Abbott C, Quinn DK (2018). Targeted Electroconvulsive Therapy for Super Refractory Status Epilepticus: A Case Report and Literature Review. Psychosomatics, 59:302-305.","DOI":"10.1016\/j.psym.2017.10.004"},{"key":"key-10.14336\/AD.2021.0302-146","doi-asserted-by":"crossref","unstructured":"Ahmed J, Metrick M, Gilbert A, Glasson A, Singh R, Ambrous W, et al (2018). Electroconvulsive Therapy for Super Refractory Status Epilepticus. J ECT, 34:e5-e9.","DOI":"10.1097\/YCT.0000000000000450"},{"key":"key-10.14336\/AD.2021.0302-147","doi-asserted-by":"crossref","unstructured":"Chen JW, Wasterlain CG (2006). Status epilepticus: pathophysiology and management in adults. Lancet Neurol, 5:246-56.","DOI":"10.1016\/S1474-4422(06)70374-X"},{"key":"key-10.14336\/AD.2021.0302-148","doi-asserted-by":"crossref","unstructured":"Liu A, Pang T, Herman S, Pascual-Leone A, Rotenberg A (2013). Transcranial magnetic stimulation for refractory focal status epilepticus in the intensive care unit. Seizure, 22:893-6.","DOI":"10.1016\/j.seizure.2013.06.014"},{"key":"key-10.14336\/AD.2021.0302-149","doi-asserted-by":"crossref","unstructured":"Eldaief MC, Press DZ, Pascual-Leone A (2013). Transcranial magnetic stimulation in neurology: A review of established and prospective applications. Neurol Clin Pract, 3:519-526.","DOI":"10.1212\/01.CPJ.0000436213.11132.8e"},{"key":"key-10.14336\/AD.2021.0302-150","doi-asserted-by":"crossref","unstructured":"Allen CH, Kluger BM, Buard I (2017). Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature. Pediatr Neurol, 68:3-17.","DOI":"10.1016\/j.pediatrneurol.2016.12.009"},{"key":"key-10.14336\/AD.2021.0302-151","doi-asserted-by":"crossref","unstructured":"Thordstein M, Constantinescu R (2012). Possibly lifesaving, noninvasive, EEG-guided neuromodulation in anesthesia-refractory partial status epilepticus. Epilepsy Behav, 25:468-72.","DOI":"10.1016\/j.yebeh.2012.07.026"},{"key":"key-10.14336\/AD.2021.0302-152","doi-asserted-by":"crossref","unstructured":"VanHaerents S, Herman ST, Pang T, Pascual-Leone A, Shafi MM (2015). Repetitive transcranial magnetic stimulation; A cost-effective and beneficial treatment option for refractory focal seizures. Clin Neurophysiol, 126:1840-2.","DOI":"10.1016\/j.clinph.2014.12.004"},{"key":"key-10.14336\/AD.2021.0302-153","doi-asserted-by":"crossref","unstructured":"Winston KR, Levisohn P, Miller BR, Freeman J (2001). Vagal nerve stimulation for status epilepticus. Pediatr Neurosurg, 34:190-2.","DOI":"10.1159\/000056018"},{"key":"key-10.14336\/AD.2021.0302-154","doi-asserted-by":"crossref","unstructured":"De Herdt V, Waterschoot L, Vonck K, Dermaut B, Verhelst H, Van Coster R, et al (2009). Vagus nerve stimulation for refractory status epilepticus. Eur J Paediatr Neurol, 13:286-9.","DOI":"10.1016\/j.ejpn.2008.05.004"},{"key":"key-10.14336\/AD.2021.0302-155","doi-asserted-by":"crossref","unstructured":"Patwardhan RV, Dellabadia J Jr, Rashidi M, Grier L, Nanda A (2005). Control of refractory status epilepticus precipitated by anticonvulsant withdrawal using left vagal nerve stimulation: a case report. Surg Neurol, 64:170-3.","DOI":"10.1016\/j.surneu.2004.11.026"},{"key":"key-10.14336\/AD.2021.0302-156","doi-asserted-by":"crossref","unstructured":"O'Neill BR, Valeriano J, Synowiec A, Thielmann D, Lane C, Wilberger J (2011). Refractory status epilepticus treated with vagal nerve stimulation: case report. Neurosurgery, 69:E1172-5.","DOI":"10.1227\/NEU.0b013e318223b979"},{"key":"key-10.14336\/AD.2021.0302-157","doi-asserted-by":"crossref","unstructured":"Dibu\u00e9-Adjei M, Brigo F, Yamamoto T, Vonck K, Trinka E (2019). Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review. Brain Stimul, 12:1101-1110.","DOI":"10.1016\/j.brs.2019.05.011"},{"key":"key-10.14336\/AD.2021.0302-158","doi-asserted-by":"crossref","unstructured":"Hamdi H, Robin E, Stahl JP, Doche E, Azulay JP, Chabardes S, et al (2019). Anterior Thalamic Stimulation Induced Relapsing Encephalitis. Stereotact Funct Neurosurg, 97:132-136.","DOI":"10.1159\/000499072"},{"key":"key-10.14336\/AD.2021.0302-159","doi-asserted-by":"crossref","unstructured":"Kaufmann E, Bartolomei F, Boon P, Chabardes S, Colon AJ, Eross L, et al (2020). European Expert Opinion on ANT-DBS therapy for patients with drug-resistant epilepsy (a Delphi consensus). Seizure, 81:201-209.","DOI":"10.1016\/j.seizure.2020.08.015"},{"key":"key-10.14336\/AD.2021.0302-160","doi-asserted-by":"crossref","unstructured":"Sherdil A, Chabard\u00e8s S, David O, Piallat B (2020). Coherence between the hippocampus and anterior thalamic nucleus as a tool to improve the effect of neurostimulation in temporal lobe epilepsy: An experimental study. Brain Stimul, 13:1678-1686.","DOI":"10.1016\/j.brs.2020.09.026"},{"key":"key-10.14336\/AD.2021.0302-161","doi-asserted-by":"crossref","unstructured":"Hamani C, Hodaie M, Chiang J, del Campo M, Andrade DM, Sherman D, et al (2008). Deep brain stimulation of the anterior nucleus of the thalamus: effects of electrical stimulation on pilocarpine-induced seizures and status epilepticus. Epilepsy Res, 78:117-23.","DOI":"10.1016\/j.eplepsyres.2007.09.010"},{"key":"key-10.14336\/AD.2021.0302-162","doi-asserted-by":"crossref","unstructured":"D'Giano CH, Del C Garc\u00eda M, Pomata H, Rabinowicz AL (2001). Treatment of refractory partial status epilepticus with multiple subpial transection: case report. Seizure, 10:382-5.","DOI":"10.1053\/seiz.2001.0521"},{"key":"key-10.14336\/AD.2021.0302-163","doi-asserted-by":"crossref","unstructured":"Ng YT, Kerrigan JF, Rekate HL (2006). Neurosurgical treatment of status epilepticus. J Neurosurg, 105:378-81.","DOI":"10.3171\/ped.2006.105.5.378"},{"key":"key-10.14336\/AD.2021.0302-164","doi-asserted-by":"crossref","unstructured":"Schrader DV, Steinbok P, Connolly M (2009). Urgent, resective surgery for medically refractory, convulsive status epilepticus. Eur J Paediatr Neurol, 13:10-7.","DOI":"10.1016\/j.ejpn.2008.01.011"},{"key":"key-10.14336\/AD.2021.0302-165","doi-asserted-by":"crossref","unstructured":"Fran\u00e7ois LL, Manel V, Rousselle C, David M (2003). Le r\u00e9gime c\u00e9tog\u00e8ne \u00e0 vis\u00e9e anti-\u00e9pileptique: son utilisation chez 29 enfants \u00e9pileptiques [Ketogenic regime as anti-epileptic treatment: its use in 29 epileptic children]. Arch Pediatr, 10:300-6. French.","DOI":"10.1016\/S0929-693X(03)00030-7"},{"key":"key-10.14336\/AD.2021.0302-166","doi-asserted-by":"crossref","unstructured":"Nabbout R, Mazzuca M, Hubert P, Peudennier S, Allaire C, Flurin V, et al (2010). Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia, 51:2033-7.","DOI":"10.1111\/j.1528-1167.2010.02703.x"},{"key":"key-10.14336\/AD.2021.0302-167","doi-asserted-by":"crossref","unstructured":"Bodenant M, Moreau C, Sejourn\u00e9 C, Auvin S, Delval A, Cuisset JM, et al (2008). Int\u00e9r\u00eat du r\u00e9gime c\u00e9tog\u00e8ne dans le traitement d'un \u00e9tat de mal \u00e9pileptique r\u00e9sistant de l'adulte [Interest of the ketogenic diet in a refractory status epilepticus in adults]. Rev Neurol (Paris), 164:194-9. French.","DOI":"10.1016\/j.neurol.2007.08.009"},{"key":"key-10.14336\/AD.2021.0302-168","doi-asserted-by":"crossref","unstructured":"Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG (2010). The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. Epilepsia, 51:1083-5.","DOI":"10.1111\/j.1528-1167.2009.02388.x"},{"key":"key-10.14336\/AD.2021.0302-169","doi-asserted-by":"crossref","unstructured":"Cervenka MC, Hartman AL, Venkatesan A, Geocadin RG, Kossoff EH (2011). The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. Neurocrit Care, 15:519-24.","DOI":"10.1007\/s12028-011-9546-3"},{"key":"key-10.14336\/AD.2021.0302-170","doi-asserted-by":"crossref","unstructured":"Heeley A, Pugh RJ, Clayton BE, Shepherd J, Wilson J (1978). Pyridoxol metabolism in vitamin B6-responsive convulsions of early infancy. Arch Dis Child, 53(10):794-802.","DOI":"10.1136\/adc.53.10.794"},{"key":"key-10.14336\/AD.2021.0302-171","doi-asserted-by":"crossref","unstructured":"Mills PB, Struys E, Jakobs C, Plecko B, Baxter P, Baumgartner M, et al (2006). Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med, 12:307-9.","DOI":"10.1038\/nm1366"},{"key":"key-10.14336\/AD.2021.0302-172","doi-asserted-by":"crossref","unstructured":"Nakagawa E, Tanaka T, Ohno M, Yamano T, Shimada M (1997). Efficacy of pyridoxal phosphate in treating an adult with intractable status epilepticus. Neurology, 48(5):1468-9.","DOI":"10.1212\/WNL.48.5.1468"},{"key":"key-10.14336\/AD.2021.0302-173","doi-asserted-by":"crossref","unstructured":"Arayakarnkul P, Chomtho K (2019). Treatment options in pediatric super-refractory status epilepticus. Brain Dev, 41:359-366.","DOI":"10.1016\/j.braindev.2018.11.011"},{"key":"key-10.14336\/AD.2021.0302-174","doi-asserted-by":"crossref","unstructured":"K\u00f6hrmann M, Huttner HB, Gotthardt D, Nagel S, Berger C, Schwab S (2006). CSF-air-exchange for pharmacy refractory status epilepticus. J Neurol, 253:1100-1.","DOI":"10.1007\/s00415-006-0181-4"},{"key":"key-10.14336\/AD.2021.0302-175","doi-asserted-by":"crossref","unstructured":"Zeiler FA, Matuszczak M, Teitelbaum J, Gillman LM, Kazina CJ (2015). Magnesium sulfate for non-eclamptic status epilepticus. Seizure, 32:100-8.","DOI":"10.1016\/j.seizure.2015.09.017"},{"key":"key-10.14336\/AD.2021.0302-176","doi-asserted-by":"crossref","unstructured":"Tan WW, Chan DWS, Lee JH, Thomas T, Menon AP, Chan YH (2015). Use of Magnesium Sulfate Infusion for the Management of Febrile Illness-Related Epilepsy Syndrome: A Case Series. Child Neurol Open, 2(1):2329048X14550067.","DOI":"10.1177\/2329048X14550067"},{"key":"key-10.14336\/AD.2021.0302-177","doi-asserted-by":"crossref","unstructured":"Gomes D, Pimentel J, Bentes C, Aguiar de Sousa D, Antunes AP, Alvarez A, Silva ZC (2018). Consensus Protocol for the Treatment of Super-Refractory Status Epilepticus. Acta Med Port, 31(10):598-605.","DOI":"10.20344\/amp.9679"},{"key":"key-10.14336\/AD.2021.0302-178","doi-asserted-by":"crossref","unstructured":"Gorter JA, van Vliet EA, Aronica E (2015). Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav, 49:13-6.","DOI":"10.1016\/j.yebeh.2015.04.047"},{"key":"key-10.14336\/AD.2021.0302-179","doi-asserted-by":"crossref","unstructured":"Nelson SE, Varelas PN (2018). Status Epilepticus, Refractory Status Epilepticus, and Super-refractory Status Epilepticus. Continuum (Minneap Minn), 24:1683-1707.","DOI":"10.1212\/CON.0000000000000668"},{"key":"key-10.14336\/AD.2021.0302-180","doi-asserted-by":"crossref","unstructured":"Betjemann JP, Lowenstein DH (2015). Status epilepticus in adults. Lancet Neurol, 14:615-24.","DOI":"10.1016\/S1474-4422(15)00042-3"},{"key":"key-10.14336\/AD.2021.0302-181","doi-asserted-by":"crossref","unstructured":"Tiamkao S, Pranboon S, Thepsuthammarat K, Sawanyawisuth K (2015). Incidences and outcomes of status epilepticus: A 9-year longitudinal national study. Epilepsy Behav, 49:135-7.","DOI":"10.1016\/j.yebeh.2015.04.040"},{"key":"key-10.14336\/AD.2021.0302-182","doi-asserted-by":"crossref","unstructured":"Rossetti AO, Logroscino G, Bromfield EB (2006). A clinical score for prognosis of status epilepticus in adults. Neurology, 66:1736-8.","DOI":"10.1212\/01.wnl.0000223352.71621.97"},{"key":"key-10.14336\/AD.2021.0302-183","doi-asserted-by":"crossref","unstructured":"Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB (2008). Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol, 255:1561-6.","DOI":"10.1007\/s00415-008-0989-1"},{"key":"key-10.14336\/AD.2021.0302-184","doi-asserted-by":"crossref","unstructured":"Gao Q, Ou-Yang TP, Sun XL, Yang F, Wu C, Kang T, Kang XG, Jiang W (2016). Prediction of functional outcome in patients with convulsive status epilepticus: the END-IT score. Crit Care, 20:46.","DOI":"10.1186\/s13054-016-1221-9"},{"key":"key-10.14336\/AD.2021.0302-185","doi-asserted-by":"crossref","unstructured":"Cooper AD, Britton JW, Rabinstein AA (2009). Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol, 66:1505-9.","DOI":"10.1001\/archneurol.2009.273"},{"key":"key-10.14336\/AD.2021.0302-186","doi-asserted-by":"crossref","unstructured":"Fountain NB, Lothman EW (1995). Pathophysiology of status epilepticus. J Clin Neurophysiol, 12(4):326-42.","DOI":"10.1097\/00004691-199507000-00004"},{"key":"key-10.14336\/AD.2021.0302-187","doi-asserted-by":"crossref","unstructured":"Fujikawa DG (1996). The temporal evolution of neuronal damage from pilocarpine-induced status epilepticus. Brain Res, 725:11-22.","DOI":"10.1016\/0006-8993(96)00203-X"},{"key":"key-10.14336\/AD.2021.0302-188","doi-asserted-by":"crossref","unstructured":"Mazarati AM, Baldwin RA, Sankar R, Wasterlain CG (1998). Time dependent decrease in the effectiveness of antiepileptic drugs during the course of self-sustaining status epilepticus. Brain Res, 814:179-85.","DOI":"10.1016\/S0006-8993(98)01080-4"},{"key":"key-10.14336\/AD.2021.0302-189","doi-asserted-by":"crossref","unstructured":"Arancibia-Carcamo IL, Kittler JT (2009). Regulation of GABAA receptor membrane trafficking and synaptic localization. Pharmacol Ther, 123:17-31.","DOI":"10.1016\/j.pharmthera.2009.03.012"},{"key":"key-10.14336\/AD.2021.0302-190","doi-asserted-by":"crossref","unstructured":"Rahman S (2015). Pathophysiology of mitochondrial disease causing epilepsy and status epilepticus. Epilepsy Behav, 49: 71-5.","DOI":"10.1016\/j.yebeh.2015.05.003"},{"key":"key-10.14336\/AD.2021.0302-191","doi-asserted-by":"crossref","unstructured":"Cock HR, Tong X, Hargreaves I, Heales SJR, Clark JP, Patsalos PN, et al (2002). Mitochondrial dysfunction associated with neuronal death following status epilepticus in rat. Epilepsy Res, 48:157-68.","DOI":"10.1016\/S0920-1211(01)00334-5"},{"key":"key-10.14336\/AD.2021.0302-192","doi-asserted-by":"crossref","unstructured":"Marchi N, Granata T, Freri E, Ciusani E, Ragona F, Puvenna V, et al (2011). Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One, 28:e18200.","DOI":"10.1371\/journal.pone.0018200"},{"key":"key-10.14336\/AD.2021.0302-193","doi-asserted-by":"crossref","unstructured":"Friedman A, Dingledine R (2011). Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia, 52 Suppl 3:33-9.","DOI":"10.1111\/j.1528-1167.2011.03034.x"},{"key":"key-10.14336\/AD.2021.0302-194","doi-asserted-by":"crossref","unstructured":"Henshall DC (2013). MicroRNAs in the pathophysiology and treatment of status epilepticus. Front Mol Neurosci, 6:37.","DOI":"10.3389\/fnmol.2013.00037"},{"key":"key-10.14336\/AD.2021.0302-195","doi-asserted-by":"crossref","unstructured":"Hantus S Epilepsy Emergencies (2016). Continuum (Minneap Minn), 22(1 Epilepsy): 173-90.","DOI":"10.1212\/CON.0000000000000285"},{"key":"key-10.14336\/AD.2021.0302-196","doi-asserted-by":"crossref","unstructured":"Terrone G, Frigerio F, Balosso S, Ravizza T, Vezzani A (2019). Inflammation and reactive oxygen species in status epilepticus: Biomarkers and implications for therapy. Epilepsy Behav, 101(Pt B):106275.","DOI":"10.1016\/j.yebeh.2019.04.028"},{"key":"key-10.14336\/AD.2021.0302-197","doi-asserted-by":"crossref","unstructured":"McElroy PB, Liang LP, Day BJ, Manisha P (2017). Scavenging reactive oxygen species inhibits status epilepticus-induced neuroinflammation. Exp Neurol, 298:13-22.","DOI":"10.1016\/j.expneurol.2017.08.009"},{"key":"key-10.14336\/AD.2021.0302-198","doi-asserted-by":"crossref","unstructured":"Paudel YN, Shaikh MF, Chakraborti A, Kumari Y, Aledo-Serrano A, Aleksovska K, et al (2018). HMGB1:a common biomarker and potential target for TBI, neuroinflammation, epilepsy, and cognitive dysfunction. Front Neurosci, 12:628.","DOI":"10.3389\/fnins.2018.00628"},{"key":"key-10.14336\/AD.2021.0302-199","doi-asserted-by":"crossref","unstructured":"Walker LE, Frigerio F, Ravizza T, Ricci E, Tse K, Jenkins RE, et al (2017). Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. J Clin Invest, 127:2118-32.","DOI":"10.1172\/JCI92001"},{"key":"key-10.14336\/AD.2021.0302-200","doi-asserted-by":"crossref","unstructured":"Henshall DC, Hamer HM, Pasterkamp RJ, Goldstein DB, Kjems J, Prehn JH, et al (2016). MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol, 15:1368-76.","DOI":"10.1016\/S1474-4422(16)30246-0"},{"key":"key-10.14336\/AD.2021.0302-201","doi-asserted-by":"crossref","unstructured":"Wang J, Yu JT, Tan L, Tian Y, Ma J, Tan C, et al (2015). Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy. Sci Rep, 5:9522.","DOI":"10.1038\/srep09522"},{"key":"key-10.14336\/AD.2021.0302-202","doi-asserted-by":"crossref","unstructured":"Wang X, Sun Y, Tan Z, Che N, Ji A, Luo X, et al (2016). Serum microRNA-4521 is a potential biomarker for focal cortical dysplasia with refractory epilepsy. Neurochem Res, 41:905-12.","DOI":"10.1007\/s11064-015-1773-0"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aginganddisease.org\/fileup\/2152-5250\/PDF\/ad-0-0-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T21:34:31Z","timestamp":1627508071000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2021.0302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":202,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2021.0302","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}